iSpecimen Return on Equity

iSpecimen (ISPC) currently reports a ROE of -579.2%. That is below the Healthcare sector average of -75.59%. Use the charts on this page to explore iSpecimen's ROE history and peer comparisons.

iSpecimen's ROE of -579.2% is lower than the Healthcare sector average of -75.59%. That is roughly 666.2% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but iSpecimen's current -579.2% should be judged against Healthcare norms (sector average: -75.59%) and against ISPC's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -579.2%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is -75.59%. From there, open related valuation or income-statement pages for iSpecimen, and consider following ISPC for alerts when major investors trade the stock.

iSpecimen is classified in the Healthcare sector. On ROE, it currently shows -579.2% versus a sector average near -75.59%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ISPC with unrelated industries.